Cingulate (CING) Receivables - Other (2023 - 2026)

Cingulate's (CING) quarterly Receivables - Other came in at $19041.0 in Q3 2025, down 2.78% on a QoQ basis from $19585.0 in Q2 2025.

Cingulate (CING) Receivables - Other (2023 - 2026) Analysis & Trends

Cingulate (CING) has 3 years of Receivables - Other data on file, last reported at $19041.0 in Q3 2025.

Quarterly Receivables - Other changed N/A year-over-year to $19041.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $19041.0 (up 145.33% YoY) and the FY2024 annual result came in at $26325.0, changed N/A from the prior year.
Receivables - Other retreated to $19041.0 in Q3 2025, from $19585.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $41573.0 in Q1 2025 to a low of -$29634.0 in Q3 2023.
A 3-year average of $10752.5 and a median of $19313.0 in 2025 frame the typical range for Receivables - Other.
The widest YoY moves for Receivables - Other: up 435.94% in 2025, down 435.94% in 2025.
Tracing CING's Receivables - Other over 3 years: stood at -$29634.0 in 2023, then surged by 188.83% to $26325.0 in 2024, then slipped by 27.67% to $19041.0 in 2025.
The last three Receivables - Other figures came in at $19041.0 (Q3 2025), $19585.0 (Q2 2025), and $41573.0 (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cingulate	72.85 Mn	72.85 Mn	-

Download Data